Schedule 13G ownership disclosure

Prelude Therapeutics, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 74065P101

Event date: 2024-12-31

Filing-level shares
5,489,130
Percent of class
9.5%
  • Vaddi Krishna

    Shares: 5,489,130 · Class: 9.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-25-000784
Form type
SCHEDULE 13G/A
Filer
Prelude Therapeutics Inc
CIK
CIK 1678660
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub